Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Double-Blind Method (0):
Recent article
Double-Blind Method
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Abstract
The omega-3 (n-3) fatty acids docosahexaenoic acid and eicosapentaenoic acid, along with γ-linolenic acid and antioxidants, may modulate systemic inflammatory response and improve oxygenation and outcomes in patients with acute lung injury.
To determine if dietary su...
|
PMID: 21976613
PDF is available here.
PDF is available here.
Ideggyogyaszati szemle (64)9-10 2011
Abstract
Antiepileptic drug randomized controlled trial (RCT) design has been criticized in the near past. Designs emphasize conventions and regulations more than clinical aspects. In the new study that scrutinized RCT patient recruitment has also raised important ethical issues. The time has...
|
PMID: 22059369
PDF is available here.
PDF is available here.
Abstract
Men at risk for prostate cancer may concurrently experience chronic prostatitis or pelvic pain. We evaluated the effect of dutasteride on prostatitis-like symptoms in the REDUCE study population.
|
PMID: 21849186
PDF is available here.
PDF is available here.
Abstract
Polidocanol sclerotherapy for hydrocele or spermatocele combines high efficiency with low morbidity, but the optimal dose is not known. We compared the efficacy and morbidity of 2 or 4 ml polidocanol sclerotherapy for hydrocele or spermatocele.
|
PMID: 21849198
PDF is available here.
PDF is available here.
Abstract
We investigated the role of the renin-angiotensin system in women with signs and symptoms of ischemia without obstructive coronary artery disease (CAD). Although microvascular dysfunction has been suggested to explain this syndrome and recently was found to predict adverse outcomes, the mechanisms a...
|
PMID: 21982660
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)14 2011
Abstract
We enrolled neonates with HSV disease in two parallel, identical, double-blind, placebo-controlled studies. Neonates with central nervous system (CNS) involvement were enrolled in one study, and neonates with skin, eye, and mouth involvement only were enrolled in the other. After completing a regime...
|
PMID: 21991950
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)13 2011
Abstract
We enrolled 3493 infants receiving antibiotics for suspected or proven serious infection and randomly assigned them to receive two infusions of either polyvalent IgG immune globulin (at a dose of 500 mg per kilogram of body weight) or matching placebo 48 hours apart. The primary outcome was death or...
|
PMID: 21962214
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)13 2011
Abstract
We conducted a single-center, randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive cytisine or matching placebo for 25 days; participants in both groups received a minimal amount of counseling during the study. The primary outcome measure was sustained,...
|
PMID: 21991893
PDF is available here.
PDF is available here.
Abstract
Hepatic encephalopathy (HE) is a common and serious complication of liver disease. Minimal HE has major impact on all aspects of a patient's life. The aim of this study was to asses the efficacy of probiotics in minimal hepatic encephalopathy in patients with cirrhosis of the liver.
|
PMID: 21922877
PDF is available here.
PDF is available here.
Abstract
We hypothesized that early EUS-CPN would reduce pain and morphine consumption, increase quality of life (QOL), and prolong survival....
|
PMID: 21844506
PDF is available here.
PDF is available here.
Abstract
These results suggest that the parent hormone, progesterone, and triazolam have discordant neuropharmacological mechanisms of action. Additional research is necessary to determine the degree to which neurosteroids influence sex differences in benzodiazepine use and abuse....
|
PMID: 21808190
PDF is available here.
PDF is available here.